AR124048A1 - Inhibidores de la btk - Google Patents
Inhibidores de la btkInfo
- Publication number
- AR124048A1 AR124048A1 ARP210103131A ARP210103131A AR124048A1 AR 124048 A1 AR124048 A1 AR 124048A1 AR P210103131 A ARP210103131 A AR P210103131A AR P210103131 A ARP210103131 A AR P210103131A AR 124048 A1 AR124048 A1 AR 124048A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- containing heterocycle
- bicyclic
- membered mono
- independently
- Prior art date
Links
- 229940124291 BTK inhibitor Drugs 0.000 title 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 3
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- -1 N(Ra)2 Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000005494 pyridonyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable de este, donde: Het es fenilo, un heteroarilo de 5 - 6 miembros o un N-(alquilo C₁-C₃)piridonilo; X⁰ es N, X¹ es C, X² es N y X⁴ es N; X⁰ es CR⁰, X¹ es C, X² es N y X⁴ es N; X⁰ es CR⁰, X¹ es N, X² es C y X⁴ es N; X⁰ es CR⁰, X¹ es N, X² es C y X⁴ es CH; o X⁰ es CR⁰, X¹ es C, X² es N y X⁴ es CH; R⁰ es H, halo, metilo, halometilo, ciclopropilo, CN o fenilo; R¹ es H o alquilo C₁-C₃, alcoxi C₁-C₃, haloalquilo C₁-C₃ o un heterociclo que contiene oxígeno monocíclico de 4 - 7 miembros; R³ es H o halo; X³ está ausente, es CH₂, CH₂CH₂, O, O-CH₂*, O-CH₂CH₂*, NH, N(CH₃)-*, CH₂N(CH₃)-* o NH-CH₂*, donde * indica el punto de unión a R²; cuando X³ está ausente, es CH₂ o CH₂CH₂, R² es un heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido al núcleo bicíclico o a X³ a través de un átomo de nitrógeno del anillo (unido en N); cuando X³ es CH₂, CH₂CH₂, O, O-CH₂*, NH, N(CH₃)-*, CH₂N(CH₃)-* o NH-CH₂*, R² es un heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido a X³ a través de un átomo de carbono del anillo (unido en C), un heterociclo que contiene oxígeno mono o bicíclico de 4 - 7 miembros, un carbociclilo mono o bicíclico de 3 - 12 miembros, o un heteroarilo de 5 - 6 miembros; y cuando X³ es O-CH₂-CH₂*, R² está ausente, es un heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido a X³ a través de un átomo de carbono del anillo (unido en C) o un grupo alquilo C₁-C₃, siempre que, cuando R² esté ausente, X³ esté directamente conectado a R⁴; el heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido en N, el heterociclo que contiene oxígeno de 4 - 7 miembros, el carbociclo mono o bicíclico de 3 - 12 miembros, el heteroarilo de 5 - 6 miembros, y el grupo de alquilo C₁-C₃ representado por R² se sustituyen con un grupo representado por R⁴ y opcionalmente se sustituyen con uno a tres grupos representados por R¹⁰, siempre que, cuando el heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido en N contiene dos átomos de nitrógeno del anillo, el heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido en N, representado por R², se sustituye opcionalmente en N con un grupo representado por R⁵ y se sustituye opcionalmente de manera adicional con uno o dos grupos representados por R¹⁰; el heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido en C se sustituye en N con un grupo representado por R⁵ y se sustituye opcionalmente de manera adicional con uno a tres grupos representados por R¹⁰; R⁴ es un compuesto del grupo de fórmulas (2); R⁵ es un compuesto del grupo de fórmulas (3); cada R⁶ es independientemente H, CN, alquilo C₁-C₃, haloalquilo C₁-C₃, N(Rᵃ)₂ o CH₂N(Rᵃ)₂, donde cada Rᵃ es independientemente H, alquilo C₁-C₃ o cicloalquilo C₃-C₆; cada R⁶ es independientemente H, alquilo C₁-C₃, haloalquilo C₁-C₃ o cicloalquilo C₃-C₆; cada R⁷ es independientemente H, alquilo C₁-C₂, fluoroalquilo C₁-C₂ o cicloalquilo C₃-C₆; R⁸ es H o alquilo C₁-C₃; cada R¹⁰ es halo, alquilo C₁-C₃ o cicloalquilo C₃-C₆; R¹¹ es H o N(R¹²)₂; cada R¹² es independientemente H o alquilo C₁-C₃; R¹³ es CN o F; R¹⁴ es halo; cada n es independientemente 0 ó 1; cada p es independientemente 1 ó 2; y q es 1 ó 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063113515P | 2020-11-13 | 2020-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR124048A1 true AR124048A1 (es) | 2023-02-08 |
Family
ID=78828007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210103131A AR124048A1 (es) | 2020-11-13 | 2021-11-12 | Inhibidores de la btk |
Country Status (14)
Country | Link |
---|---|
US (1) | US20240083900A1 (es) |
EP (1) | EP4244223A1 (es) |
JP (1) | JP2023549360A (es) |
KR (1) | KR20230119134A (es) |
CN (1) | CN116783199A (es) |
AR (1) | AR124048A1 (es) |
AU (1) | AU2021377891A1 (es) |
BR (1) | BR112023009116A2 (es) |
CL (1) | CL2023001367A1 (es) |
CO (1) | CO2023007677A2 (es) |
MX (1) | MX2023005626A (es) |
TW (1) | TW202233624A (es) |
UY (1) | UY39517A (es) |
WO (1) | WO2022104079A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023086575A1 (en) * | 2021-11-12 | 2023-05-19 | Biogen Ma Inc. | Btk inhibitors |
WO2023220049A1 (en) * | 2022-05-10 | 2023-11-16 | Biogen Ma Inc. | Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide |
WO2024083111A1 (zh) * | 2022-10-18 | 2024-04-25 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
WO2024117205A1 (ja) * | 2022-11-30 | 2024-06-06 | 北興化学工業株式会社 | 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013055645A1 (en) * | 2011-10-12 | 2013-04-18 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
CA2918242C (en) * | 2013-07-31 | 2022-06-21 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
EP3891149A4 (en) * | 2018-12-07 | 2022-09-07 | Sunshine Lake Pharma Co., Ltd. | RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
-
2021
- 2021-11-12 EP EP21823425.0A patent/EP4244223A1/en active Pending
- 2021-11-12 AR ARP210103131A patent/AR124048A1/es unknown
- 2021-11-12 WO PCT/US2021/059168 patent/WO2022104079A1/en active Application Filing
- 2021-11-12 UY UY0001039517A patent/UY39517A/es unknown
- 2021-11-12 KR KR1020237019845A patent/KR20230119134A/ko unknown
- 2021-11-12 AU AU2021377891A patent/AU2021377891A1/en active Pending
- 2021-11-12 TW TW110142205A patent/TW202233624A/zh unknown
- 2021-11-12 US US18/036,853 patent/US20240083900A1/en active Pending
- 2021-11-12 MX MX2023005626A patent/MX2023005626A/es unknown
- 2021-11-12 CN CN202180089379.6A patent/CN116783199A/zh active Pending
- 2021-11-12 BR BR112023009116A patent/BR112023009116A2/pt unknown
- 2021-11-12 JP JP2023528245A patent/JP2023549360A/ja active Pending
-
2023
- 2023-05-11 CL CL2023001367A patent/CL2023001367A1/es unknown
- 2023-06-13 CO CONC2023/0007677A patent/CO2023007677A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4244223A1 (en) | 2023-09-20 |
UY39517A (es) | 2022-06-30 |
US20240083900A1 (en) | 2024-03-14 |
WO2022104079A1 (en) | 2022-05-19 |
CO2023007677A2 (es) | 2023-09-08 |
CN116783199A (zh) | 2023-09-19 |
KR20230119134A (ko) | 2023-08-16 |
MX2023005626A (es) | 2023-07-31 |
JP2023549360A (ja) | 2023-11-24 |
BR112023009116A2 (pt) | 2023-10-03 |
CL2023001367A1 (es) | 2024-01-05 |
TW202233624A (zh) | 2022-09-01 |
AU2021377891A1 (en) | 2023-07-06 |
AU2021377891A9 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR124048A1 (es) | Inhibidores de la btk | |
AR110922A1 (es) | Compuestos inhibidores del vih | |
AR108838A1 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
AR108875A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
AR093364A1 (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
AR113929A1 (es) | Compuestos heterocíclicos | |
AR100059A1 (es) | Compuestos útiles como inmunomoduladores | |
AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
AR103252A1 (es) | Compuestos de quinazolina | |
AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR117616A1 (es) | Compuestos anti-vih | |
AR065824A1 (es) | Sulfonilbenzamidas sustituidas con heterociclos bloqueantes de los canales de sodio,formulaciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del dolor y particularmente del dolor cronico. | |
AR093580A1 (es) | Inhibidores bmi-1 de pirimidina sustituidos | |
AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR089120A1 (es) | Compuestos herbicidas | |
AR089550A1 (es) | Compuestos quimicos | |
AR107840A1 (es) | INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g |